Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 8/20 | 0.52 |
| ▸ | KDR | P35968 | 7/20 | 0.52 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.49 |
| ▸ | PGK1 | P00558 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532044 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1HTTKDM4EEGFR | |
| SCHEMBL27248760 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HTTKDM4EEGFR | |
| SCHEMBL10958235 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HTTKDM4EEGFR | |
| SCHEMBL30615149 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HTTKDM4EEGFR | |
| SCHEMBL30615130 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HTTKDM4EEGFR | |
| Propanol SCHEMBL28411721 | 0.89 | HTT (0.60) | SMN1; SMN2ALDH1A1HTTKDM4EEGFR | |
| SCHEMBL8094841 | 0.87 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1HTTKDM4EEGFR | |
| SCHEMBL26755290 | 0.87 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1HTTKDM4EEGFR | |
| SCHEMBL24931339 | 0.86 | EGFR (0.51) | SMN1; SMN2ALDH1A1HTTKDM4EEGFR | |
| SCHEMBL31620287 | 0.86 | EGFR (0.51) | SMN1; SMN2ALDH1A1HTTKDM4EEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 425 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640095-A | Diaryl amine derivative containing aliphatic carboxyl and preparation method and application thereof | 山东大学 | 2023-08-25 | — | — | CN | claimed |
| CN-114409636-B | Quinazolinone compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 沈阳药科大学 | 2023-04-18 | — | — | CN | claimed |
| CN-111138371-A | 2, 4-dichloro-6, 7-dimethoxyquinazoline solvate and preparation method thereof | 重庆威尔德浩瑞医药化工有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-103819467-B | The preparation method and its usage of quinazoline derivant | 中国科学院福建物质结构研究所 | 2019-03-08 | — | — | CN | claimed |
| CN-103819467-A | Preparation method and application of quinazoline derivative | FUJIAN MATTER STRUCTURE | 2014-05-28 | — | — | CN | claimed |
| US-8492543-B2 | Method for producing quinazoline derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-07-23 | — | — | US | claimed |
| CN-101747323-B | Method for preparing alfuzosin hydrochloride | BEIJING INST TECHNOLOGY | 2013-04-17 | — | — | CN | claimed |
| EP-2189450-B1 | METHOD FOR PRODUCING QUINAZOLINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2011-12-21 | — | — | EP | claimed |
| US-20110152521-A1 | Method for Producing Quinazoline Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | claimed |
| EP-2189450-A1 | METHOD FOR PRODUCING QUINAZOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-05-26 | — | — | EP | claimed |
| EP-1994024-A2 | QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| WO-2007099323-A2 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | claimed |
| JP-59155372-A | — | — | None | — | — | JP | disclosed |
| EP-4747243-A1 | LIGANDS AND COMPOSITIONS AND METHODS OF USE THEREOF | Baylor College of Medicine (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748838-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| JP-S59155372-A | 6,7-DIMETHOXYQUINAZOLINE DERIVATIVE | SANKYO CO LTD | 1984-09-04 | — | — | JP | disclosed |
| US-4102885-A | Process for preparing 2,4-dihaloquinazolines | BRISTOL-MYERS COMPANY (US) | 1978-07-25 | — | — | US | disclosed |
| US-4053600-A | ANTIINFLAMMATORY AGENTS, HYPOTENSIVE AGENTS | SANDOZ, INC. (US) | 1977-10-11 | — | — | US | disclosed |
| US-4011323-A | ANTIOBESITY AND ANTIDIABETIC | SANDOZ, INC. (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630527-B2 | Broad spectrum anti-cancer compounds | YTHDF3, YTHDF1, YTHDF2 | SMN1; SMN2 2389/4885ALDH1A1 4643/4885HTT 2596/4885 |
| US-20110152521-A1 | Method for Producing Quinazoline Derivative | HNMT, AZI2, GNMT | SMN1; SMN2 2922/4885ALDH1A1 1808/4885HTT 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.